EGFR and non-small cell lung carcinoma: However, the benefits of these regimens might vary by mutation profile; recently development of next-generation sequencing (NGS) technologies allows detection of a large number of concurrent mutations in patients with EGFR-mutant NSCLC that further complicate the situation [6].